Galectin Therapeutics Planning Clinical Trials for Early 2013 to Treat Fatty Liver Disease with Advanced Fibrosis After Recent FDA Meeting
Published: Aug 07, 2012
NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced its clinical development program for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease, with advanced fibrosis. Galectin Therapeutics has selected GR-MD-02, a novel galectin inhibitor discovered by the Company, as its lead candidate for NASH, which is expected to enter clinical trials in early 2013. NASH represents a major unmet medical need, affecting 9 to 15 million Americans, with the only treatment option being liver transplantation.